Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance
The pharmaceutical firm is investing EUR 30m in a new biotech company focused on precision medicine to treat infections.
by andreas lønstrup, translated by daniel pedersen
German pharmaceutical firm Boehringer Ingelheim is investing EUR 30m to combat drug-resistant bacteria. Forming an alliance with Evotec and Biomérieux, the firms have established Aurobac Therapeutics, a biotech firm with a precision medicine approach to infection treatment, as reported by Fierce Biotech.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
